Oct. 11, 2012, 10:43 a.m.

Sonic Healthcare's bid to buy Healthscope's pathology businesses across Australia has largely been knocked back, with the competition regulator this morning ruling against Sonic's bid forHealthscope's Queensland pathology business.

The Australian Competition and Consumer Commission this morning said Sonic's bid for the Queensland business was rejected becauseit was "likely to have the effect of substantially lessening competition in the market for the supply for community pathology services in Queensland."

This is due to a range of factors, including the reputation, professional relationships, network of collection centres and testing capability it has established in Queensland, supported by its strong position in other pathology markets in Australia.

If Healthscope were removed as a competitive constraint, it is not likely to be replaced in a timely and sufficient way by the new entry or expansion of other pathology providers in Queensland.

The ACCC has approved Sonic's takeover of Healthscope's Western Australian pathology business.

In Western Australia, the ACCC recognised that a number of significant pathology providers will remain following the proposed acquisition, such that the removal of Healthscope is not likely to result in a substantial lessening of competition in that market, ACCC chairman Rod Sims said ina statement.

Last month,Sonic and Healthscope said they were dropping plans for Sonic to buy Healthscope's pathology businesses in New South Wales and the Australian Capital Territory, blaming delays in the ACCC decision-making process. This left just the WA and Queensland businesses for ACCC consideration.

Healthscope chief executive Robert Cook told BusinessDay recently thatit was conducting a strategic review of its pathology business in NSW and ACT, and it hadformed the view it is a long term holder of that business."

See the original post here:
Regulator denies Sonic's full bid for Healthscope Save

New research study Digital Pathology Market - Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/ Cloud Based) and Whole Slide Image Storage - Global Trends & Forecast till 2017 created by MarketsandMarkets has been recently published by Market Publishers Ltd. The report informs that the worldwide digital pathology market is estimated to be USD 191.00 million in 2012.

London, UK (PRWEB) October 10, 2012

The leading players operating in the global digital pathology marketplace are Aperio Technologies, Inc., Ventana Medical Systems, Leica Microsystems GmbH, Digipath, and Hamamatsu Photonics.

New research study Digital Pathology Market - Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/ Cloud Based) and Whole Slide Image Storage - Global Trends & Forecast till 2017 created by MarketsandMarkets has been recently published by Market Publishers Ltd.

Report Details:

Title: Digital Pathology Market - Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/ Cloud Based) and Whole Slide Image Storage - Global Trends & Forecast till 2017

Published: October, 2012

Pages: 233

Price: US$ 4,650.00

http://marketpublishers.com/report/technologies_electronics/electronic_devices/digital_pathology_market_slide_scanners_whole_slide_imaging_analytics_image_analysis_software_delivery_modes_web_based_cloud_based_n_whole_slide_image_s.html

See the original post here:
Worldwide Digital Pathology Market Prospects Studied in New Topical Study Now Available at MarketPublishers.com

Sonic Healthcare's bid to buy Healthscope's pathology businesses across Australia has largely been knocked back, with the competition regulator this morning ruling against Sonic's bid forHealthscope's Queensland pathology business.

The Australian Competition and Consumer Commission this morning said Sonic's bid for the Queensland business was rejected becauseit was "likely to have the effect of substantially lessening competition in the market for the supply for community pathology services in Queensland."

This is due to a range of factors, including the reputation, professional relationships, network of collection centres and testing capability it has established in Queensland, supported by its strong position in other pathology markets in Australia.

If Healthscope were removed as a competitive constraint, it is not likely to be replaced in a timely and sufficient way by the new entry or expansion of other pathology providers in Queensland.

Advertisement

The ACCC has approved Sonic's takeover of Healthscope's Western Australian pathology business.

In Western Australia, the ACCC recognised that a number of significant pathology providers will remain following the proposed acquisition, such that the removal of Healthscope is not likely to result in a substantial lessening of competition in that market, ACCC chairman Rod Sims said ina statement.

Last month,Sonic and Healthscope said they were dropping plans for Sonic to buy Healthscope's pathology businesses in New South Wales and the Australian Capital Territory, blaming delays in the ACCC decision-making process. This left just the WA and Queensland businesses for ACCC consideration.

Healthscope chief executive Robert Cook told BusinessDay recently thatit was conducting a strategic review of its pathology business in NSW and ACT, and it hadformed the view it is a long term holder of that business."

See the article here:
Regulator denies Sonic's full bid for Healthscope

Sonic Healthcare's bid to buy Healthscope's pathology businesses across Australia has largely been knocked back, with the competition regulator this morning ruling against Sonic's bid forHealthscope's Queensland pathology business.

The Australian Competition and Consumer Commission this morning said Sonic's bid for the Queensland business was rejected becauseit was "likely to have the effect of substantially lessening competition in the market for the supply for community pathology services in Queensland."

This is due to a range of factors, including the reputation, professional relationships, network of collection centres and testing capability it has established in Queensland, supported by its strong position in other pathology markets in Australia.

If Healthscope were removed as a competitive constraint, it is not likely to be replaced in a timely and sufficient way by the new entry or expansion of other pathology providers in Queensland.

Advertisement

The ACCC has approved Sonic's takeover of Healthscope's Western Australian pathology business.

In Western Australia, the ACCC recognised that a number of significant pathology providers will remain following the proposed acquisition, such that the removal of Healthscope is not likely to result in a substantial lessening of competition in that market, ACCC chairman Rod Sims said ina statement.

Last month,Sonic and Healthscope said they were dropping plans for Sonic to buy Healthscope's pathology businesses in New South Wales and the Australian Capital Territory, blaming delays in the ACCC decision-making process. This left just the WA and Queensland businesses for ACCC consideration.

Healthscope chief executive Robert Cook told BusinessDay recently thatit was conducting a strategic review of its pathology business in NSW and ACT, and it hadformed the view it is a long term holder of that business."

See the article here:
ACCC denies Sonic's bid for Healthscope

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4d2gld/digital_pathology) has announced the addition of the "Digital Pathology Market - Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/ Cloud Based) and Whole Slide Image Storage - Global Trends & Forecast till 2017" report to their offering.

The life science industry is now witnessing the second decade of Biologic Revolution. The adoption and up gradation of technology is increasing rapidly. Conventional practices are being replaced by advanced technologies. The perception of pathological laboratories needs to be improved as the consumer expectations and government regulations towards improved patient safety, accurate diagnosis, Electronic Medical Records (EMR) as well as personalized medicines are growing. Pathology plays a significant role in patient care. Digital pathology serves this purpose by providing a facility for digital transformation of pathology and laboratory medicine.

Digital pathology is currently gaining momentum as pathologists are seeking to achieve workflow efficiency and cost cutting in the pathological process. It provides ready access to premium quality slide images, enabling better and fast diagnosis, as well as preservation of these digital slides for future reference. The digital pathology market is driven by the factors such as reduction in laboratory expenses, improvement in operational efficiency, and treatment decisions and patient care. The rising prevalence of cancer, increasing trends in drug development, companion diagnostics, and ease of consultation are the major drivers that are slated to propel this market. However, a few pivotal factors restraining the growth of this market are FDA regulations in some regions, high cost of Digital Pathology Systems (DPS), technological problems, and conservative outlook of pathologists. There are a few well-established firms and several small ones operating in this industry. The major players in the market are Aperio Technologies, Inc. (U.S.), Ventana Medical Systems (U.S.), Leica Microsystems GmbH (Germany), Digipath (U.S.), and Hamamatsu Photonics (Japan).

The global digital pathology market is broadly segmented into two categories based on its products and application. The product category includes scanners, analytics (visualization software, information management systems and image analysis platforms), storage and communication (sharing services, software), while the application category comprises human pathology and animal pathology. Both these markets are dominated by North America in 2012, followed by Europe, Asia, and Rest of the World (RoW). The global digital pathology market is estimated to be $191.00 million in 2012, and is poised to grow at a CAGR of 12% to reach $336.61 million by 2017.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Digital Pathology: Rationale For Adoption

Read the original here:
Research and Markets: Digital Pathology Market - Slide Scanners, Analytics, Delivery Modes and Whole Slide Image ...

October 3, 2012 Waterloo, ON – Huron Technologies International Inc., recently was awarded 1st prize in two categories at the 2nd International Scanner Contest (ISC) held in Berlin, Germany and announced in Prague, Czech Republic, at the European Congress of...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/i57tHcxkN8A/huron-technologies-awarded-1st-prize-in-fluorescence-scanning-contest.html

Meet A Pioneer in Digital Pathology and Virtual Microscopy: Dr. Béla Molnár, Semmelweis University & 3DHISTECH Dr. Béla Molnár is an award-winning Physician at Semmelweis University’s 2nd Department of Internal Medicine in Hungary, where he specializes in gastroenterology and colorectal...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/rEj6KgeNYCg/meet-a-pioneer-in-digital-pathology-and-virtual-microscopy.html

Investments into the clinical digital pathology space continue to be made. Recent news of Definiens private funding, expanding on their portfolio and experience in research and development and pharmaceutical shows increasing interest in the clinical market. Good news for healthcare...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/9rm_AjGl7kc/definiens-closes-10-million-round-to-grow-its-clinical-digital-pathology-business.html

Source: HealthImaging Olympus and Sony have entered into a business alliance agreement and a capital alliance agreement through a third-party allotment of Olympus' common shares to Sony. As part of the agreement, Sony will invest 50 billion Japanese Yen, which...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/B9tTwiMR5Y8/sony-invests-640m-in-olympus-eyes-imaging-market.html

MarketsandMarkets: Global Digital Pathology Market Worth $336.6 Million by 2017 (via PR Newswire) The market size mentioned here comes in less (multi-billion dollar size) than was previously mentioned here, here, here, here and here. No way for me to know...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/pl7kyd7N-QY/marketsandmarkets-global-digital-pathology-market-worth-3366-million-by-2017.html

New Mexico, USA 9/30/2012 – Indica Labs, Inc. proudly announces the availability of HALO™, the next generation image analysis platform for digital pathology. HALO is designed to be the fastest, most scalable, user-friendly image analysis software the industry has witnessed....

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/XzaaQ6G1AUw/indica-labs-release-halo-next-generation-image-analysis-1.html

DigiPath today announces PathTrade, the exchange initiative that provides affordable and innovative digital pathology solutions, while also providing means for underserved communities to access pathology educational and medical experts throughout the world.

Henderson, Nevada (PRWEB) October 04, 2012

PathTrade provides existing telepathology users an affordable means to upgrade discontinued telepathology systems with a DigiPath solution. DigiPath will provide $500 to $5,000 as trade-in credit for upgrading to PathScope and/or PathLive value. Additionally, DigiPath will refurbish system, and deploy system without any additional fees, in communities in need of pathology educational and medical experts. DigiPath has identified many underserved communities in Africa, India, Mideast, Southeast Asia, Caribbean, and South America, for installations in 2012.

DigiPath has been asked numerous times to assist in providing systems in countries of need of pathology expertise, said Steve Barbee, Vice President of DigiPath, Inc., Vice President of DigiPath, Inc. DigiPath is delighted to not only assist our clients in upgrading systems, but in bringing advanced pathology practices to underserved communities worldwide.

Please email info(at)digipath(dot)biz if interested in upgrading your telepathology system for world health benefits.

About DigiPath, Inc.

DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPaths advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 750 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide. DigiPath has offices within Kansas, California, Maryland, and Nevada. Please see http://digipath.biz for more details.

SAFE HARBOR STATEMENT

This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

DigiPath Media Relations DigiPath, inc. (702) 527-2060 Email Information

Excerpt from:
DigiPath Provides Affordable Upgrade & Pathology Access to Areas in Need

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/3hhcmt/manual_of) has announced the addition of Elsevier Science and Technology's new report "Manual of Techniques in Invertebrate Pathology. Edition No. 2" to their offering.

The second edition of Manual of Techniques in Invertebrate Pathology is written by an international group of experts that contribute a broad array of techniques for the identification, isolation, culture, bioassay, propagation, and storage of the major groups of entomopathogens.

The manual provides general and specific background to experienced insect pathologists, biologists, and entomologists who work with pathogen groups that are new to them. It is also useful as a laboratory manual for courses in insect pathology and biological control and related areas of study. Safety testing of entomopathogens in mammals and complementary techniques for the preparation of entomopathogens are included as well as broader methods for the study of specimens such as microscopy and molecular techniques.

This manual concentrates primarily on practical step-by-step aspects of the techniques, but also provides the reader with a short history, rationale for usage, guides to supplemental literature, plus recipes for media, fixatives, and stains.

- Step-by-step instructions for the latest techniques on how to isolate, identify, culture, bioassay and store the major groups of entomopathogens

- New edition fully updated to address changes in the taxonomy of the vast majority of taxa

- Discussion of safety testing of entomopathogens in mammals and also broader methods such as microscopy and molecular techniques

- Provides extensive supplemental literature and recipes for media, fixatives and stains

For more information visit http://www.researchandmarkets.com/research/3hhcmt/manual_of

View post:
Research and Markets: Manual of Techniques in Invertebrate Pathology. Edition No. 2

LEXINGTON, Mass., Oct.3, 2012 /PRNewswire/ --StrataDx, a leader in anatomic pathology services, announced today the appointments of Jim Agnello as Chief Financial Officer, Greg Richard as Executive Vice President of Sales & Marketing, and Steve Casper to its Board of Directors.StrataDx provides clinicians with high-quality pathology services in the fields of dermatology, urology, podiatry, oral pathology, gastroenterology and gynecology.

Jim Agnello, CPA, joins StrataDx as the Chief Financial Officer and brings over two decades of financial & laboratory operational expertise. Mr. Agnello served as the Chief Financial Officer of Clarient and Nodality and most recently, as the Vice President of Operations for Healthtronics, Inc. He also spent 18 years with SmithKline Beecham in a variety of senior financial positions. Jim has a a Master's Degree in Accounting from the Wharton School at the University of Pennsylvania and a Bachelors Degree in Business Administration from Rutgers, the State University of New Jersey.

Greg Richard joins the company as the Executive Vice President of Sales & Marketing and brings extensive senior sales leadership expertise in not only the laboratory industry, but in Managed Care, Biotech, and Clinical Trials as well. Most recently, he was the Chief Commercial Officer at Signal Genetics, a specialty molecular testing Company, and served previously as the Sales Officer for LabCorp's Northeast Division and the Vice President of Managed Care and Global Sales and Marketing for Clinical Trials at Quest Diagnostics. Greg received a B.A. from Westminster College.

Steven E. Casper has been named to the board of StrataDx. He is currently the Chief Executive Officer of National Dentex Corporation. Mr. Casper has significant experience developing successful health care organizations. Prior to National Dentex, Mr. Casper was involved the founding and development of AmeriPath and Dermpath Diagnostics, both leading providers of pathology services. Mr. Casper served as the President of Dermpath Diagnostics, a division of Quest Diagnostics, Inc. and previously held senior executive roles at AmeriPath and Summit Partners. Steven received a B.A from Boston College.

"These appointments represent a significant milestone for StrataDx. Greg and Jim both have stellar track records of driving growth and generating value in their respective organizations," said Pat Noland, Chief Executive Officer, StrataDx.

Richard Novak, Chairman of the StrataDx Board of Directors adds, "We are pleased to welcome Steven to the Board. His breadth of knowledge and expertise will contribute to the ongoing evolution of StrataDx as a best in class pathology services organization."

About StrataDx

(www.strataDx.com)

StrataDx is a full service anatomic pathology laboratory that offers services in all areas of surgical pathology and cytology as well as molecular diagnostics and immunoflorescence. The pathology team is comprised of members with subspecialty board certification in dermatopathology, hematopathogy, cytopathology, nuclear medicine, clinical pathology, and the majority of the pathologists have more than two decades of medical experience. Many also have teaching appointments at some of the nation's most prestigious academic medical centers including Harvard, Tufts, and the Univ. of Pennsylvania. StrataDx services customers ranging from major regional hospitals to small, independent physician practices in more than 40 states. Headquartered in Lexington, MA, with additional locations in Cambridge, MA, the company has more than 120 employees.

About Linden Capital Partners

The rest is here:
StrataDx appoints Chief Financial Officer, Executive Vice President of Sales and Marketing, New Board Member

TUCSON, Ariz.- At this year's 29th Congress of the International Academy of Pathology (IAP 2012), Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, will unveil the latest versions of its Virtuoso digital pathology image and workflow management software and VANTAGE workflow solution for histology lab specimen tracking. IAP 2012, one of the premier pathology conferences worldwide, takes place September 30 through October 5, 2012 in Cape Town, South Africa.

"I am thrilled to be presenting our latest products at this year's IAP," explained Steve Burnell, PhD, Lifecycle Leader for Digital Pathology and Workflow for Ventana Medical Systems, Inc. "The global adoption of digital pathology and lab workflow solutions is gaining momentum, driven by benefits to laboratory efficiency and productivity, as well as improvements in patient care. As the established innovation leader in these areas, the Ventana launch of Virtuoso 5.3 - with a user interface now available in 21 languages - and VANTAGE 2.2 - with improved integration, underscores our commitment to pathologists, laboratory staff and patients to deliver the most innovative products in the industry."

Virtuoso web-based software orchestrates the digital slide workflow from the moment the slide is scanned until the slide image is viewed and the case results reported. With Virtuoso 5.3, Ventana has expanded the user interface to 21 languages, making it easy for international customers to adopt this new technology.

"I am pleased to see Ventana continue to take a leadership role in digital pathology with the latest offering of its Virtuoso software released in multiple languages. This is a reflection of the strong interest in digital pathology from labs across the globe. Virtuoso not only increases the effectiveness of labs like mine working with cases from Mexico and the US, but also enables us to improve patient care." Jesus Ellin - Yuma Regional Medical, Yuma, AZ USA.

The market-leading VANTAGE workflow solution automates, streamlines, and integrates lab work and information flow to provide increased productivity and patient safety gains. The VANTAGE 2.2 release introduces increased Laboratory Information System (LIS) integration capabilities, touchscreen workflow enhancements and case assembly improvements in response to global customers' needs. Through its integration with Virtuoso software, the VANTAGE workflow solution enables pathologists and lab managers to track the progress of a slide from preparation to digitization along with other critical slide information, giving a lab unprecedented visibility into its processes and tools to optimize lab workflow.

Ventana's newest scanner, the VENTANA iScan HT slide scanner, will also be showcased at IAP 2012. The VENTANA iScan HT is the most powerful scanner in anatomic pathology today, enabling pathologists and lab managers to optimize their digital pathology workflow with efficiency, convenience, speed, throughput and reliability for unprecedented results. The VENTANA iScan HT slide scanner is ideal for high throughput and high volume applications. It complements the VENTANA comprehensive suite of digital pathology solutions which also includes the iScan Coreo slide scanner, Virtuoso software, and the most comprehensive portfolio of research use only (RUO), CE-IVD and FDA-cleared 510(k) image analysis algorithms available.

"Since the acquisition of BioImagene two years ago, Roche and Ventana have invested heavily in Digital Pathology, bringing a wide range of innovative new products to the market. We believe that by driving the rapid adoption of digital pathology and improved workflow globally, we will help improve patient care. Our customers can expect sustained and unparalleled innovation from Ventana in the future," says Mara G. Aspinall, President of Ventana Medical Systems, Inc.

Watch the video: VENTANA iScan HT.

To view the entire suite of Ventana digital pathology and workflow products, including the Virtuoso -VANTAGE software integration, visit the Roche Diagnostics booth during the 29th Congress of the International Academy of Pathology from September 30th through October 5th, 2012 in Cape Town, South Africa.

About Ventana Medical Systems, Inc.

Read this article:
Ventana Unveils the Latest in Digital Pathology and Lab Workflow Solutions at IAP 2012 in Cape ...

MyPath software empowers the global pathology community to quickly access scattered and ever changing information critical to diagnostic pathology. Today, our new collaboration with PubMed, which contains the National Health Institutes vast biomedical resources, continues MyPath and the United States and Canadian Academy of Pathologys (USCAP) commitment to being the resource for pathology practitioners, education and professional collaboration.

Augusta, GA (PRWEB) October 01, 2012

Today, MyPath becomes a stronger tool with the announcement of USCAPs partnership with the National Institute of Healths Pub Med library. This collaboration makes all of NIHs vast biomedical resources instantly available to MyPath and USCAP members. More importantly, content available through PubMed is also available to MyPath users to store in their own personal files, make comments, and read the comments of others including those from leading experts. This truly is a game changer for the global pathology community. It has never been easier to access the worlds premiere pathology and biomedical information, commented Jeffrey L. Myers, M.D., Chair of USCAPS Innovative Educational Products Committee.

My goal is to grow USCAPs leadership in pathology education, said USCAP Executive Vice President Bruce Smoller, We were pleased to recently announce receiving ACCMEs highest recognition for all of USCAPs educational courses. Now these courses are readily accessible through MyPath on iPad and computer, anytime, anywhere.

To connect with MyPath, log on to http://www.MyPath .uscap.org.

Company Information:

The United States and Canadian Academy of Pathology (USCAP) is the leader of pathology education excellence. Dedicated to creating and disseminating pathology research, education and collaboration, USCAP empowers doctors with the latest advances to improve their daily practices. The USCAP website: http://www.uscap.org.

jeff monks

706.733.7550 Email Information

See the original post:
USCAP’s MyPath™ Announces Digital Partnership with the National Institute of Health’s PubMed

NEWCASTLE UPON TYNE, England, October 1, 2012 /PRNewswire/ --

Leica Biosystems announces the availability of the Novocastra HD menu for breast pathology, the first portfolio of independently qualified* antibodies from the new Novocastra HD range. Together with the FDA approval of the Leica BOND Oracle HER2 IHC System on April 18, 2012, this new menu affirms Leica Biosystems' position as a premier supplier of the most clinically important IHC systems and reagents for the diagnosis of breast cancer.

(Photo: http://photos.prnewswire.com/prnh/20121001/564961 )

The Novocastra HD menu for breast pathology comprises 37 products, developed following extensive research with pathologists and laboratory staff from around the globe. Novocastra HD products have been independently evaluated* by NordiQC in comparison with leading equivalents. Staining performance in Ready-to-Use format has been optimized on BOND instrumentation, delivering the crucial diagnostic confidence that underpins every patient diagnosis. Pathologists and laboratories can confidently select any Novocastra HD product, knowing that it has been externally benchmarked against leading equivalents for staining quality and diagnostic performance.

'Leica Biosystems strives to achieve the utmost customer satisfaction and improvement in patient care through the pursuit of excellence in quality', says Arnd Kaldowski, President of Leica Biosystems. 'The new Novocastra HD menu for breast pathology was developed to meet our customers' need for clinically relevant antibodies that deliver high quality staining and results patients can depend on.'

The Novocastra HD breast pathology menu of IHC antibodies comprises twelve[#] clones in a range of formats and volumes. Many BOND Ready-to-Use antibodies come in two sizes: 7 mL and a new 30 mL size for higher usage requirements. Liquid concentrates are available in an expanded range of sizes from 0.1 mL to 2 mL.

The Novocastra HD menu for breast pathology will be available for sale in the USA and EU from September 2012. Availablility in other regions will follow.

Leica Biosystems offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.

The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.

http://www.LeicaBiosystems.com

Continue reading here:
Choose Highly Definitive Antibodies for IHC with the new Leica Biosystems Novocastra HD Menu for Breast Pathology

NovoPath, Inc. announces the addition of Tami Abell to their team, who will concentrate on enriching client satisfaction in her role as Account Manager.

Princeton, NJ (PRWEB) September 29, 2012

Tami, a seasoned professional, will hit the ground running as she brings over two decades of hands-on senior level management expertise, backed by a technical background. Her qualifications include a successful track record in healthcare marketing and sales, and her extensive experience in the Healthcare Information Technology sector translates to a comprehensive understanding of this sophisticated arena. For the last 10 years, Tami has drilled down, focusing on the anatomic pathology market specifically laboratory information systems and software.

As Account Manager, Tami will be contributing to the growth of the organization by concentrating on enrichment of NovoPath client satisfaction. In her new role, Tami will act as a conduit to customers when she designs and implements NovoPaths new User Group Program, and as liaison to the New Product Development team translating client needs into viable product enhancements and solutions.

When asked about her new assignment, Tami replied, I joined NovoPath because I wanted to be part of a team actively involved in driving the Anatomic Pathology market. While my primary aim is to listen to clients, thereby increasing their level of satisfaction, I look forward to contributing to a company that is furthering the significant diagnostic advances leading to a more personalized treatment for cancer patients.

About NovoPath, Inc.:

NovoPath, Inc. develops and markets software solutions for the Anatomic Pathology Laboratory market segment that includes local, regional, national, in-house laboratories as well as community and university teaching hospitals and medical centers. Since the release of its flagship product in 1999, NovoPath, Inc. has focused exclusively on Anatomic Pathology. NovoPath's mission is to provide unique and unparalleled solutions and services to all aspects of the Anatomic Pathology sector in a way that improves workflow, reduces the probability of human error, ensures results accuracy for greater patient safety, protects patient confidentiality, and above all, produces more precise and informative diagnostic outcomes. More information is available at http://www.NovoPath.com.

Susan Holland/Public Relations Specialist NovoPath INC 336.693.9101 201 Email Information

View post:
NovoPath Hires Veteran Account Manager - Tami Abell Brings Decades of Experience to Anatomic Pathology Leader

TUCSON, Ariz., Sept. 26, 2012 /PRNewswire/ — At this year’s 29th Congress of the International Academy of Pathology (IAP 2012), Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, will unveil the latest versions of its Virtuoso digital...

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

September 30-October 2, 2012 - Vancouver, BC Visit ViewsIQ at the Annual NSH Symposium / Convention Booth #530 to learn the latest in interactive slide imaging technology. Come see your slides in a whole new way ViewsIQ has invented Panoptiq,...

Source:
http://feeds.feedburner.com/DigitalPathologyBlog